Yoon Ji Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoon Ji Choi has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Kyong Hwa Park
Division of Hemato-Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea
7 shared publications - Eun Joo Kang
Division of Hemato-oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
6 shared publications - Yeul Hong Kim
Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea
6 shared publications Alexander Miron
4 shared publications- Bose S. Kochupurakkal
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
4 shared publications Debajit K. Biswas
4 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Incidence, risk factors, and mortality of acute kidney injury in patients receiving immune checkpoint inhibitors: analysis by acute kidney injury subtype
Acute kidney injury (AKI) is a common complication in patients receiving immune checkpoint inhibitor (ICI) therapy. It can result from conventional causes or immune-mediated mechanisms. This study aimed to determine the incidence, risk factors, and clinical outcomes of all-cause AKI in patients treated with ICIs. We retrospectively analyzed adults treated with ICIs at Korea University Anam Hospital between 2015 and 2024. AKI occurring within 12 months after treatment initiation was defined according to the KDIGO (Kidney Disease: Improving Global Outcomes) criteria. It was classified as transient azotemia (recovery within 72 hours) or sustained AKI (>72 hours), including acute tubular necrosis (ATN), obstruction, and ICI-associated AKI (ICI-AKI). Among 943 patients, the overall incidence of AKI was 32.1%. ATN was most common, followed by transient azotemia, obstruction, and immune-mediated acute tubulointerstitial nephritis. Pre-existing chronic kidney disease and proton pump inhibitor use were independent risk factors for immune-mediated AKI, whereas low serum albumin, high C-reactive protein, and hepatobiliary cancers were associated with ATN. Transient azotemia and ATN were independently associated with higher mortality. Although ICI-AKI was also significantly associated with increased mortality, the association was modest and should be interpreted cautiously given the limited number of cases (n = 25). ATN and transient azotemia were more frequent than ICI-AKI and were associated with worse prognosis; ICI-AKI also showed a statistically significant but modest association with mortality. Identifying different risk factors for each subtype may help clinicians achieve earlier recognition and optimize management in patients receiving ICI therapy.
- 15 October 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Open AccessIncidence, risk factors, and mortality of acute kidney injury in patients receiving immune checkpoint inhibitors: analysis by acute kidney injury subtype
Acute kidney injury (AKI) is a common complication in patients receiving immune checkpoint inhibitor (ICI) therapy. It can result from conventional causes or immune-mediated mechanisms. This study aimed to determine the incidence, risk factors, and clinical outcomes of all-cause AKI in patients treated with ICIs. We retrospectively analyzed adults treated with ICIs at Korea University Anam Hospital between 2015 and 2024. AKI occurring within 12 months after treatment initiation was defined according to the KDIGO (Kidney Disease: Improving Global Outcomes) criteria. It was classified as transient azotemia (recovery within 72 hours) or sustained AKI (>72 hours), including acute tubular necrosis (ATN), obstruction, and ICI-associated AKI (ICI-AKI). Among 943 patients, the overall incidence of AKI was 32.1%. ATN was most common, followed by transient azotemia, obstruction, and immune-mediated acute tubulointerstitial nephritis. Pre-existing chronic kidney disease and proton pump inhibitor use were independent risk factors for immune-mediated AKI, whereas low serum albumin, high C-reactive protein, and hepatobiliary cancers were associated with ATN. Transient azotemia and ATN were independently associated with higher mortality. Although ICI-AKI was also significantly associated with increased mortality, the association was modest and should be interpreted cautiously given the limited number of cases (n = 25). ATN and transient azotemia were more frequent than ICI-AKI and were associated with worse prognosis; ICI-AKI also showed a statistically significant but modest association with mortality. Identifying different risk factors for each subtype may help clinicians achieve earlier recognition and optimize management in patients receiving ICI therapy.
- Open Access
- 31 August 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (17) , e70387
Central Nervous System Activity of Lazertinib in EGFR ‐Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‐LU20‐15 and LU21‐01
Background: Central nervous system (CNS) involvement remains a major cause of mortality in patients with epidermal growth factor receptor (EGFR)‐mutated nonsmall cell lung cancer (NSCLC), particularly, after progression on EGFR tyrosine kinase inhibitors (TKIs). This pooled analysis evaluated the efficacy of lazertinib in patients with EGFR ‐mutated NSCLC and CNS involvement, using data from two Phase II trials. Patients and Methods: Patients with EGFR ‐mutated NSCLC and CNS involvement following prior EGFR TKI therapy enrolled in the KCSG‐LU20‐15 and KCSG‐LU21‐01 were included. Overall and intracranial objective response rate (ORR), disease control rate (DCR), and progression‐free survival (PFS) were assessed. Results: Seventy‐two patients were included. The median age was 63 years and 45 patients (62.5%) had leptomeningeal metastases (LM). T790M status was positive in 7 patients, negative in 44, and unknown in 21. Intracranial tumor responses were evaluable in 46 patients; the intracranial ORR was 50.0%, and the intracranial DCR was 97.8%. The median intracranial PFS was 15.2 months. Among 66 patients evaluable for systemic response, the overall ORR and DCR were 22.7% and 97.0%, respectively. The median PFS and overall survival were 10.6 and 17.8 months, respectively. Patients with LM experienced inferior OS and intracranial PFS compared with those without LM. No significant differences in clinical outcomes were observed according to T790M status. Conclusion: Lazertinib demonstrated meaningful CNS activity in patients with EGFR ‐mutated NSCLC and CNS involvement after prior EGFR TKI exposure, including those with LM. Notably, this activity was observed in a cohort with a low prevalence of confirmed T790M positivity.
- 31 August 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (17) , e70387
Open AccessCentral Nervous System Activity of Lazertinib in EGFR ‐Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‐LU20‐15 and LU21‐01
Background: Central nervous system (CNS) involvement remains a major cause of mortality in patients with epidermal growth factor receptor (EGFR)‐mutated nonsmall cell lung cancer (NSCLC), particularly, after progression on EGFR tyrosine kinase inhibitors (TKIs). This pooled analysis evaluated the efficacy of lazertinib in patients with EGFR ‐mutated NSCLC and CNS involvement, using data from two Phase II trials. Patients and Methods: Patients with EGFR ‐mutated NSCLC and CNS involvement following prior EGFR TKI therapy enrolled in the KCSG‐LU20‐15 and KCSG‐LU21‐01 were included. Overall and intracranial objective response rate (ORR), disease control rate (DCR), and progression‐free survival (PFS) were assessed. Results: Seventy‐two patients were included. The median age was 63 years and 45 patients (62.5%) had leptomeningeal metastases (LM). T790M status was positive in 7 patients, negative in 44, and unknown in 21. Intracranial tumor responses were evaluable in 46 patients; the intracranial ORR was 50.0%, and the intracranial DCR was 97.8%. The median intracranial PFS was 15.2 months. Among 66 patients evaluable for systemic response, the overall ORR and DCR were 22.7% and 97.0%, respectively. The median PFS and overall survival were 10.6 and 17.8 months, respectively. Patients with LM experienced inferior OS and intracranial PFS compared with those without LM. No significant differences in clinical outcomes were observed according to T790M status. Conclusion: Lazertinib demonstrated meaningful CNS activity in patients with EGFR ‐mutated NSCLC and CNS involvement after prior EGFR TKI exposure, including those with LM. Notably, this activity was observed in a cohort with a low prevalence of confirmed T790M positivity.
- Open Access
- 4 August 2026
- Published by Korean Cancer Association in Cancer Research and Treatment
Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program
Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program
- 4 August 2026
- Published by Korean Cancer Association in Cancer Research and Treatment
Open AccessIntegrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program
Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program
- Open Access
- 6 May 2026
- Published by Elsevier in SSRN Electronic Journal
Treatment-free survival after two-year immune checkpoint inhibitor treatment in non-small cell lung cancer: Utilizing the Korean Health Insurance Review and Assessment Service database
Introduction Immune checkpoint inhibitors (ICIs) have improved survival in advanced non-small cell lung cancer; however, reimbursement is often limited to 2 years based on pivotal trial designs, raising concerns about disease control after cessation. We aimed to evaluate treatment-free survival (TFS), overall survival (OS), and new-onset comorbidities in patients completing 2 years of post-platinum ICI therapy using a nationwide Korean claims database. Methods Using the Health Insurance Review and Assessment Service database, 10,275 patients initiating post-platinum ICI between 2017 and 2022 were identified. Patients treated for ≥2 years were classified as completers, and others were classified as discontinuers. Comorbidity rates were compared using person-years Poisson regression; landmark analysis at 2 years served as sensitivity analysis. Results Of 10,275 patients, 786 (7.6%) completed 2 years of ICI therapy. Median TFS was 32.8 months; median OS was not reached. Among discontinuers, 47.1% initiated subsequent therapy and 24.7% died within 42 days, suggesting most discontinuations were progression-related. Despite higher crude comorbidity rates in completers, person-years adjustment revealed significantly lower incidence rates, including congestive heart failure (adjusted IRR, 0.430) and type 2 diabetes (0.581). Thyroid hormone use was the exception on landmark analysis (adjusted HR, 2.113; P=.045). Comorbidity onset was broadly distributed, with events occurring throughout follow-up, despite delayed median onset. Conclusions In this first large-scale Asian cohort study, 2-year ICI completion was associated with durable TFS and OS, and comorbidity rates remained unchanged after adjusting for differential follow-up. However, broad temporal distribution of comorbidity onset warrants long-term survivorship surveillance, particularly for thyroid dysfunction.
- 6 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTreatment-free survival after two-year immune checkpoint inhibitor treatment in non-small cell lung cancer: Utilizing the Korean Health Insurance Review and Assessment Service database
Introduction Immune checkpoint inhibitors (ICIs) have improved survival in advanced non-small cell lung cancer; however, reimbursement is often limited to 2 years based on pivotal trial designs, raising concerns about disease control after cessation. We aimed to evaluate treatment-free survival (TFS), overall survival (OS), and new-onset comorbidities in patients completing 2 years of post-platinum ICI therapy using a nationwide Korean claims database. Methods Using the Health Insurance Review and Assessment Service database, 10,275 patients initiating post-platinum ICI between 2017 and 2022 were identified. Patients treated for ≥2 years were classified as completers, and others were classified as discontinuers. Comorbidity rates were compared using person-years Poisson regression; landmark analysis at 2 years served as sensitivity analysis. Results Of 10,275 patients, 786 (7.6%) completed 2 years of ICI therapy. Median TFS was 32.8 months; median OS was not reached. Among discontinuers, 47.1% initiated subsequent therapy and 24.7% died within 42 days, suggesting most discontinuations were progression-related. Despite higher crude comorbidity rates in completers, person-years adjustment revealed significantly lower incidence rates, including congestive heart failure (adjusted IRR, 0.430) and type 2 diabetes (0.581). Thyroid hormone use was the exception on landmark analysis (adjusted HR, 2.113; P=.045). Comorbidity onset was broadly distributed, with events occurring throughout follow-up, despite delayed median onset. Conclusions In this first large-scale Asian cohort study, 2-year ICI completion was associated with durable TFS and OS, and comorbidity rates remained unchanged after adjusting for differential follow-up. However, broad temporal distribution of comorbidity onset warrants long-term survivorship surveillance, particularly for thyroid dysfunction.
- Open Access
- 1 March 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (3) , 50
Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes
Background: While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a cornerstone of therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC), resistance remains a major clinical challenge. The genomic landscape of early-stage (ES) EGFR-mutant NSCLC and its evolution to advanced-stage (AS) disease is not fully understood. This study aimed to characterize the molecular disparities between ES and AS EGFR-mutant NSCLC and to identify genomic alterations associated with EGFR-TKI treatment outcomes. Methods: We have collected and profiled the complex genomes of 121 ES and 74 AS NSCLCs to determine their molecular and clinical disparities. Furthermore, we analyzed 84 EGFR-mutant NSCLC patients who were treated with EGFR-TKIs to identify potential molecular correlates that could predict the treatment response within the clinic. Patients were stratified by progression-free survival (PFS) and overall response rate (ORR), and hazard ratio analyses were performed. Results: In the study, significant enrichment of mutations in MTOR, ATRX, STAG2, ABL1, and SPEN was observed in AS tumors, whereas ES tumors predominantly exhibited mutations activating JAK2, ERBB2, and FGFR4. In the EGFR-TKI cohort, poor responders harbored frequent mutations in TP53, KIT, and ALK, and these were associated with worse clinical outcomes. Conversely, favorable responders showed enrichment of MTOR, ATM, EP300, and PIK3R1 mutations. ALK and FANCA were linked to increased hazard, while EP300 and PIK3R1 mutations correlated with improved prognosis. Conclusions: Given the growing importance of biomarker-driven treatment in the field of oncology, our results collectively open up new therapeutic opportunities for ES NSCLC patients.
- 1 March 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (3) , 50
Open AccessMolecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes
Background: While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a cornerstone of therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC), resistance remains a major clinical challenge. The genomic landscape of early-stage (ES) EGFR-mutant NSCLC and its evolution to advanced-stage (AS) disease is not fully understood. This study aimed to characterize the molecular disparities between ES and AS EGFR-mutant NSCLC and to identify genomic alterations associated with EGFR-TKI treatment outcomes. Methods: We have collected and profiled the complex genomes of 121 ES and 74 AS NSCLCs to determine their molecular and clinical disparities. Furthermore, we analyzed 84 EGFR-mutant NSCLC patients who were treated with EGFR-TKIs to identify potential molecular correlates that could predict the treatment response within the clinic. Patients were stratified by progression-free survival (PFS) and overall response rate (ORR), and hazard ratio analyses were performed. Results: In the study, significant enrichment of mutations in MTOR, ATRX, STAG2, ABL1, and SPEN was observed in AS tumors, whereas ES tumors predominantly exhibited mutations activating JAK2, ERBB2, and FGFR4. In the EGFR-TKI cohort, poor responders harbored frequent mutations in TP53, KIT, and ALK, and these were associated with worse clinical outcomes. Conversely, favorable responders showed enrichment of MTOR, ATM, EP300, and PIK3R1 mutations. ALK and FANCA were linked to increased hazard, while EP300 and PIK3R1 mutations correlated with improved prognosis. Conclusions: Given the growing importance of biomarker-driven treatment in the field of oncology, our results collectively open up new therapeutic opportunities for ES NSCLC patients.
- Open Access
- 1 November 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (11) , 4973-4982
Unveiling the clinical impact of plasma-only mutations in non-small cell lung cancer: a Korean multicenter experience
Background: Plasma-based circulating tumor DNA (ctDNA) analysis has emerged as a promising tool to complement tissue genotyping in non-small cell lung cancer (NSCLC), particularly when tissue acquisition is limited. We investigated the clinical applicability of ctDNA analysis in Korean patients with recurrent or metastatic NSCLC. Methods: We retrospectively analyzed 132 patients with NSCLC who underwent plasma ctDNA testing between June 2017 and December 2021 in the K-MASTER project. Mutation detection rates, concordance between tissue and plasma results, and survival outcomes according to targeted therapy administration were evaluated. Clinical characteristics of plasma-only mutations were further examined. Results: Actionable mutations were identified in 43.2% of patients through combined tissue and plasma analyses. Plasma ctDNA testing revealed actionable mutations in 11.4% of patients not detected by tissue genotyping, seven of whom received targeted therapy based on plasma results. Rare co-occurring actionable alterations were found in three patients, including concurrent EGFR and KRAS or ALK and EGFR mutations, suggesting intratumoral heterogeneity or possible multiple primary cancers. Among the three cases with plasma-positive but tissue-negative results, one had biopsies from bone and one from liver, suggesting possible effects of sampling bias or clonal evolution. Patients who received targeted therapy—guided by either tissue or plasma results—demonstrated significantly improved survival compared with those who did not (P=0.03). Conclusions: Plasma-based ctDNA analysis broadens detection of actionable genomic alterations and facilitates access to targeted therapies in NSCLC, particularly when tissue biopsy is limited. These findings support integrating liquid biopsy into routine practice to optimize patient outcomes.
- 1 November 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (11) , 4973-4982
Open AccessUnveiling the clinical impact of plasma-only mutations in non-small cell lung cancer: a Korean multicenter experience
Background: Plasma-based circulating tumor DNA (ctDNA) analysis has emerged as a promising tool to complement tissue genotyping in non-small cell lung cancer (NSCLC), particularly when tissue acquisition is limited. We investigated the clinical applicability of ctDNA analysis in Korean patients with recurrent or metastatic NSCLC. Methods: We retrospectively analyzed 132 patients with NSCLC who underwent plasma ctDNA testing between June 2017 and December 2021 in the K-MASTER project. Mutation detection rates, concordance between tissue and plasma results, and survival outcomes according to targeted therapy administration were evaluated. Clinical characteristics of plasma-only mutations were further examined. Results: Actionable mutations were identified in 43.2% of patients through combined tissue and plasma analyses. Plasma ctDNA testing revealed actionable mutations in 11.4% of patients not detected by tissue genotyping, seven of whom received targeted therapy based on plasma results. Rare co-occurring actionable alterations were found in three patients, including concurrent EGFR and KRAS or ALK and EGFR mutations, suggesting intratumoral heterogeneity or possible multiple primary cancers. Among the three cases with plasma-positive but tissue-negative results, one had biopsies from bone and one from liver, suggesting possible effects of sampling bias or clonal evolution. Patients who received targeted therapy—guided by either tissue or plasma results—demonstrated significantly improved survival compared with those who did not (P=0.03). Conclusions: Plasma-based ctDNA analysis broadens detection of actionable genomic alterations and facilitates access to targeted therapies in NSCLC, particularly when tissue biopsy is limited. These findings support integrating liquid biopsy into routine practice to optimize patient outcomes.